India, Mumbai 
Dr. Gaurav Narula is a Professor of Pediatric Oncology and Health Sciences at Tata Memorial Centre, Mumbai, and a leading expert in pediatric hematology-oncology. He heads clinical and research initiatives in leukemia, lymphoma, and advanced cellular therapies, and serves as Principal Investigator of the CAR-T & Cell Therapy Center
Current Position
- Professor, Pediatric Oncology & Health Sciences, Tata Memorial Centre
- Principal Investigator, CAR-T & Cell Therapy Center (CTCTC)
- Former Convener, Pediatric Hemato-lymphoid Group (PHLG)
Education
- Fellowship, Pediatric Hematology-Oncology – Tata Memorial Centre
- MD, Pediatrics – Armed Forces Medical College
- DNB, Pediatrics – National Board of Examinations
- MBBS – Armed Forces Medical College
Professional Background
- Over 25 years of service in the Indian Navy as a Pediatrician & Hematologist
- Former: Professor & Classified Specialist, Pediatrics & Hematology, INHS Asvini, Mumbai
- Leading one of India’s largest pediatric oncology programs managing 1000+ new leukemia/lymphoma cases annually
Area of Specialization
- Pediatric Hematology & Oncology
- Leukemia & Lymphoma
- Stem Cell Transplantation
- Cellular Therapy & CAR-T
Research & Innovation Focus
- Development and expansion of CAR-T cell therapy in India
- Co-development of India’s first CAR-T therapy (with IIT Bombay collaboration)
- Building infrastructure for: Cell & gene therapy manufacturing, Clinical trials, Translational oncology research
- Focus on low-cost innovative cancer treatments for resource-limited settings
Leadership & Contributions
- Co-founder & Treasurer, Immuno-Oncology Society of India
- Founding Member & Secretary, Indian Association of Cell & Gene Therapy
- Founding Editor-in-Chief, Pediatric Hematology Oncology Journal
Additional Roles
- Member & advisor to: Department of Biotechnology (India),Indian Council of Medical Research (ICMR), Central Drugs Standard Control Organization (CDSCO).
- Extensive involvement in: Ethics committees, Clinical trial review, Translational oncology governance
All information is sourced from publicly available materials.